HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mathys, J.-M. Articles by Skolnik, P. R. Search for Related Content PubMed PubMed Citation Articles by Mathys, J.-M. Articles by Skolnik, P. R.

NF-B Modulates TNF- Production by Alveolar Macrophages in Asymptomatic HIV-Seropositive Individuals¹

Jean-Marie Mathys^*, Suzanne M. Melanson^*, Deborah J. Schiffer-Alberts^*, John P. A. Ioannidis, Henry Koziel and Paul R. Skolnik^2,*

^* Department of Medicine, Division of Geographic Medicine and Infectious Diseases, Tupper Research Institute, Tufts University-New England Medical Center, Boston, MA 02111; HIV Research Branch, Division of AIDS, National Institutes of Health, Bethesda, MD 20892; and Division of Pulmonary and Critical Care Medicine, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Local TNF- production in different organs may affect HIV replication and pathogenesis. Alveolar macrophages (AMs) obtained by bronchoalveolar lavage from asymptomatic HIV-seropositive and HIV-seronegative individuals did not spontaneously release TNF-, but LPS stimulation of these cells significantly increased TNF- production. We tested whether NF-B affects TNF- production by AMs using N-tosyl-L-phenylalanine chloromethylketone (TPCK) or N-benzoyl-L-tyrosine ethyl ester (BTEE), which inhibit the degradation of IB, or tricyclodecan-9-yl-xanthogenate-potassium (D609), which inhibits phospholipase C. Alveolar macrophages were exposed to LPS alone and with the chemical protease inhibitors TPCK, BTEE, and D609. NF-B DNA binding induced by LPS treatment of AMs was inhibited by TPCK, BTEE, and D609. These agents also inhibited TNF- mRNA and TNF- protein production. After 24 h, the levels of TNF- mRNA reached equilibrium, as assessed by RT-PCR. The levels of NF-B mRNA remained constant under all conditions. The levels of IB- mRNA were similar after 30, 60, and 180 min, but the IB-ß mRNA concentration was initially low and increased over time under all conditions. IB- and IB-ß protein production was not affected by the chemical protease inhibitors. Our data show that TNF- production by LPS-stimulated AMs from asymptomatic HIV-seropositive and -seronegative individuals is regulated via the phospholipase C pathway and by NF-B DNA binding activity without obvious changes in IB- or IB-ß protein concentrations.

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
The lung is a frequent target organ for complications related to HIV-1 infection (1, 2, 3). Alveolar macrophages (AMs),³ the predominant pulmonary immune cells, mediate first-line host defense, direct pulmonary immune responses, and modulate inflammatory responses in the lungs. Alveolar macrophages are permissive for HIV-1 infection in vitro and may be a major reservoir for HIV-1 (4). Although HIV-1 infection in the lungs is generally latent, HIV-1 replicates in the lungs during advanced AIDS (5), Pneumocytis carinii pneumonia (5), and Mycobacterium tuberculosis infection (6, 7, 8, 9, 10, 11).

HIV replication is enhanced in vitro by several of the cytokines that are produced in the lungs of HIV-seropositive patients (12). In particular, TNF- produced by macrophages may be important in HIV pathogenesis. During M. tuberculosis pneumonia, enhanced HIV-1 replication correlates with increased TNF- levels in bronchoalveolar lavage (BAL) fluid (10). TNF-, a proinflammatory cytokine released by AMs, enhances HIV-1 replication by inducing NF-B DNA binding and by activating the HIV long-terminal repeat in cells other than AMs (13).

NF-B is an important cellular transcription factor and a crucial component of the host’s response to infection. In most unstimulated cells, NF-B is retained in the cytoplasm by a specific inhibitor, IB. A variety of agents can induce phosphorylation-dependent degradation of IB-, unmasking the nuclear localization signal on p65 and subsequently activating NF-B. After activation, IB dissociates from the complex and triggers the translocation of NF-B into the nucleus, where it binds to a consensus sequence in the promoter regions of several cellular genes as well as to the HIV long terminal repeat (14, 15, 16). Inhibitors of IB- degradation often decrease gene activation and reduce the production of inflammatory cytokines (17). N-tosyl-L-phenylalanine chloromethyl ketone (TPCK) modifies the sulfhydryl group in NF-B, thus preventing its binding to DNA (18). The exact mechanism by which N-benzoyl-L-tyrosine ethyl ester (BTEE) blocks NF-B binding activity is not fully known. TPCK, but not BTEE, inhibits NF-B activity and the accompanying IB- degradation, most likely by inhibiting the protease responsible for IB- degradation (19, 20). Delineation of the mechanism(s) that modulates TNF- production by AMs may provide important insights into HIV pathogenesis in the lungs. Furthermore, a better understanding of the factors that influence TNF- release in the lungs may identify potential targets for modifying local HIV replication. The purpose of this study was to characterize the mechanism(s) of TNF- release by AMs obtained from HIV-seropositive and -seronegative individuals.

In this paper we describe the use of TPCK, BTEE, and D609 to block TNF- production by inhibiting NF-B DNA binding activity in AMs from asymptomatic HIV-seropositive persons. These inhibitors may act at several steps of the pathway between LPS stimulation and TNF- production. Our data suggest that one such mechanism is the stabilization of the IB protein, and therefore the IB-NF-B complex, with an associated blunting of LPS-induced TNF- production.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials

Escherichia coli 0127:B8 LPS was purchased from Difco (Detroit, MI), TPCK and BTEE were purchased from Sigma (St. Louis, MO), and D609 (tricyclodecan-9-yl-xanthogenate-potassium K) was purchased from Biomol (Plymouth Meeting, PA).

Study subjects

This study was approved by the institutional review boards of the New England Medical Center and Beth Israel Deaconess Medical Center (Boston, MA). All persons were recruited prospectively, and all participants provided informed consent before participating in the study. Participants had normal spirometric characteristics and did not have active pulmonary disease. For each participant, age, sex, smoking status, medical history, and current medications were recorded on standardized forms. In addition, for the HIV-seropositive individuals, information related to HIV risk factors, peripheral CD4 count, HIV RNA in plasma, medications (including antiretroviral therapy), and HIV-related diseases were recorded.

Each patient completed a comprehensive questionnaire regarding medical history (including details of HIV-1 infection, related infections, and medications) and underwent a physical examination and bronchoalveolar lavage.

Alveolar macrophages and PBMC were obtained from 11 asymptomatic healthy HIV-seropositive individuals, six men and five women, with a mean age of 36 yr (range, 33–48 yr) and from six HIV-seronegative individuals (control subjects), four men and two women. HIV risk factors included homosexuality, i.v. drug use, and heterosexual contact. All patients were taking medications, including AZT, 3TC, ritonavir, ddI, d4T, nevirapine, ddC, and indinavir, individually or in combination.

Bronchoalveolar lavage

AMs were obtained from patients by bronchoalveolar lavage using standard technique (21). Briefly, after topical 2% lidocaine anesthesia was applied to the oropharynx, a flexible fiber-optic bronchoscope was passed into the airways and wedged in a segment of the right middle lobe. Bronchoalveolar lavage was performed by instilling six to eight 50-ml aliquots of warm nonbacteriostatic saline (0.9%) followed by gentle suction after each aliquot was infused. In general, 75% of the instilled saline was recovered. The lavage fluid was collected into sterile traps in a closed system. The cells were separated from the pooled lavage fluid by centrifugation at 100 x g for 10 min at 4°C, washed in cold RPMI 1640 supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (Sigma), and counted on a hemocytometer. Cells were resuspended at 10⁷ cells/ml in RPMI 1640.

Culture of BAL cells

Cells retrieved from HIV-seropositive and -seronegative subjects by bronchoscopy were placed on ice before processing, at 10⁷ cells/ml, in RPMI 1640 with penicillin (100 U/ml), streptomycin (100 µg/ml), and amphotericin (0.25 µg/ml; Life Technologies, Grand Island, NY). The cells were transferred to 24-well tissue culture plates in RPMI 1640 supplemented with penicillin (100 U/ml), streptomycin (100 µg/ml), and amphotericin (0.25 µg/ml); 2 mM L-glutamine (Life Technologies); 10% FCS (HyClone, Logan, UT); and 2 mM HEPES (BAL medium) at a concentration of 5 x 10⁵ cells/ml. The cells were either stimulated with LPS at 100 ng/ml or incubated in medium alone at 37°C in 5% CO₂. The cells were plated at a density of 0.5 x 10⁶/well and incubated 16 h at 37°C. The medium was replaced with fresh medium containing the inhibitors and incubated for another 4 h before RNA extraction and for 24 h before TNF- determination in the supernatant fluids. Cell viability was assessed by trypan blue exclusion and microscopy.

Cytokine ELISA

TNF- concentrations in the supernatant fluids were determined using a commercially available ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s instructions. The limit of detection for TNF- was 4.4 pg/ml. Supernatant fluids were diluted as necessary to assure OD readings within the linear portion of the assay.

Electrophoretic mobility shift assay (EMSA)

Nuclear extracts were prepared using the method of Andrews (22). Briefly, the cells were suspended in hypotonic buffer (10 mM HEPES (pH 7.4), 1.5 mM MgCl₂, 10 mM KCl, 0.5 mM DTT, and 0.2 mM PMSF) and incubated on ice for 10 min. Nuclei were separated by centrifugation and resuspended in buffer (20 mM HEPES (pH 7.9), 25% glycerol, 420 mM NaCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, and 0.2 mM PMSF) for 20 min on ice. Supernatant fluids were clarified by centrifugation and stored at -70°C. Then, 2–5 µg of the clarified extracts were used for the shift reaction and incubated for 20 min at room temperature with a NF-B probe containing the consensus sequence (5'-AGTTGAGGGGACTTTCCCAGGC-3'; Promega, Madison, WI). Supershift assays were performed with the addition of an Ab directed against p65 (Santa Cruz Biotechnology, Santa Cruz, CA). Abs against p65 was added to the extracts after addition of the probe and incubated for 1 h at room temperature before resolution on a 5% polyacrylamide gel. The probe was end labeled with [-³²P]ATP. The reaction mixture was analyzed on an 8% polyacrylamide gel run in 0.5x TBE. The gels were dried, and x-ray film was exposed for 16 h.

RNA extraction

Total RNA was extracted in situ using Trizol, as recommended by the manufacturer (Life Technologies). Briefly, 1 ml of Trizol was added to the culture plate, mixed, and incubated for 5 min at room temperature. The solution was transferred to a microcentrifuge tube, and 200 µl of chloroform was added, vortex mixed, and incubated for 10 min. After centrifugation for 5 min, the aqueous layer was transferred to a fresh tube, and RNA was precipitated by adding an equal volume of isopropanol. After centrifugation, the RNA pellet was dried and dissolved in 50 µl of sterile, diethylpyrocarbonate-treated water. The RNA concentration was determined by optical density measurements.

Immunoprecipitation and Western blot

Cytoplasmic extracts were prepared from alveolar macrophages treated with LPS and TPCK, BTEE, or D609. The extracts, with prestained markers (National Diagostics, Atlanta, GA), were subjected to electrophoresis on a denaturing 10% polyacrylamide-SDS gel, transferred to a nylon membrane (Hybond-N, Amersham, Arlington Heights, IL), and analyzed by Western blot. Blots were blocked with 5% BSA in PBS, followed by incubation with 0.1 µg/ml of primary anti-IB-, anti-IB-ß (Santa Cruz Biotechnology), or both for 1 h at room temperature. Anti-rabbit alkaline phosphatase conjugate was the secondary Ab, and the incubation was continued for 45 min at room temperature. Enzymatic activity was detected using vector red (Vector, Burlingame, CA) or 5-bromo-4-chloro-indoyl-phosphate, 4-toluidine salt and nitro blue tetrazolium chloride (Roche, Indianapolis, IN). Alternatively, the extracts were preclarified by incubation with protein A-Sepharose CL-4B (Pharmacia, Piscataway, NJ) for 1 h at 4°C. After centrifugation, the solution was incubated overnight at 4°C with Abs directed against IB-.

Immunoprecipitation of the complexes was performed by incubation with 50 µl of protein A-Sepharose, followed by incubation for 4 h at 4°C. After extensive washing, the proteins were solubilized in 40 µl of Laemmli buffer and resolved by SDS-PAGE electrophoresis. Separated proteins were electroblotted to nitrocellulose, treated with blocking buffer, and incubated for 1 h at room temperature with IB- Ab, which was followed, after washing, by incubation with a second alkaline-phosphatase-conjugated Ab. The enzymatic activity was detected using Vector red (Vector) or 5-bromo-4-chloro-indoyl-phosphate, 4-toluidine salt and nitro blue tetrazolium chloride.

RT-PCR

RNA (1–2 µg) was reverse transcribed using the kit Advantage RT for PCR (Clontech, Palo Alto, CA) according to the manufacturer’s instructions. The final cDNA product was diluted to 100 µl with sterile diethylpyrocarbonate-treated water. An aliquot of the cDNA was used for specific cytokine PCR using the appropriate TNF-, IB-, IB-ß, and actin primers (CLP; Clontech or Tufts University Core Synthesis Facility). The conditions for amplification reactions were as described by the manufacturer. An aliquot of the amplified product was run on a 1.5% agarose gel at 125 V for 45 min in TBE or on a 10% PAGE gel run in 1x TBE. After electrophoresis, the gel was stained for 5 min in ethidium bromide (1%) and photographed. PCR primers for actin were used as an internal control. In some cases, the sense primer was 5' end labeled with ³²P. After electrophoresis, the gel was dried, and autoradiography was performed.

PCR and flow cytometry

Nonadherent cells and AMs were separated by adhesion to plastic for 16 h at 37°C and resuspended in 50 µl of 4% paraformaldehyde in PBS for 30 min at 4°C. The cells were washed in PBS, incubated for 5 min at 37°C in a solution of 120 µg/ml of pronase, briefly incubated at 95°C for 3 min, and centrifuged. The cell pellet was resuspended in a mixture containing 200 pmol of primers (SK38 and SK39)/reaction; 200 µM each of dGTP, dATP, and dCTP; 196 µM dTTP; 4 µM dUTP-11-DIG (Roche), 40 U of RNasin (Promega), and 2.5 U of Taq polymerase. The cycling conditions were as follows: denaturation at 95°C for 1 min, annealing at 55°C for 1 min, and elongation at 72°C for 1 min, for a total of 35 cycles. The samples were centrifuged and washed extensively before being incubated for 30 min at room temperature with anti-DIG-FITC (1/1000; Roche), washed, and analyzed by flow cytometry using a Becton Dickinson flow cytometer (Mountain View, CA).

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Cytokine and chemokine production by AMs from HIV-seropositive and -seronegative subjects differed between lung and peripheral blood cells (J.-M. Mathys, manuscript in preparation). Spontaneous TNF- production by AMs from HIV-seropositive patients was negligible, but increased after LPS stimulation. TNF- protein production was measured by ELISA in the supernatant fluids after 24 h. Spontaneous TNF- production by AM from HIV-seropositive (n = 11) and -seronegative (n = 6) subjects was very low (mean, 196 and 176 pg/ml, respectively). However, after LPS stimulation, BAL cells from HIV-seronegative subjects produced more TNF- than those from asymptomatic HIV-infected subjects (mean, 7018 compared with 3766 pg/ml; p = 0.012, by nonparametric Wilcoxon matched pair, signed ranks test for paired samples). In this study we analyzed the production of TNF- by AM and the roles of NF-B and IB in this process.

Effects of TPCK and BTEE on TNF- production by AM

We studied the effects of TPCK and BTEE (serine proteases) on the production of TNF- by AMs. To determine whether the chemical protease inhibitors act in a dose-dependent manner, we analyzed the responses of AMs after incubation with various concentrations of chemical protease inhibitors. Cells from patients (n = 3) were cultured for 16 h in plastic tissue culture plates. The nonadherent cells from BAL were removed, and TPCK and BTEE were added to AMs at various concentrations in 2 ml of fresh medium.

Treatment of AMs with TPCK and BTEE caused a dose-dependent inhibition of TNF- production with almost complete inhibition at 50 µg/ml (Fig. 1, A and B). Cell viability, as determined by vital dye exclusion (trypan blue), was always >85% after incubation of AMs for 24 h with the chemical protease inhibitor at the concentrations used. We next determined the effects of TPCK, BTEE, and D609 on TNF- production from AMs from HIV-seropositive subjects and HIV-seronegative controls. LPS induced TNF- production after 24-h culture, but TPCK and BTEE almost completely inhibited this effect in both HIV-seropositive and -seronegative subjects (Fig. 2).

View larger version (23K): [in this window] [in a new window]   FIGURE 1. The effects of various concentrations of TPCK and BTEE on TNF- production by AMs obtained from three HIV-seropositive study subjects compared with that in LPS-stimulated controls. BAL cells (5 x 105/well) were incubated for 24 h in the presence of LPS (100 ng/ml) alone or with TPCK (0–50 µg/ml; A) or BTEE (0–50 µg/ml; B) after nonadherent cells were removed. Supernatant fluids were collected after 24 h and assayed for TNF- by ELISA. NS, not stimulated; LPS, stimulated with LPS.

View larger version (20K): [in this window] [in a new window]   FIGURE 2. The effects of TPCK, BTEE, and D609 on TNF- production by AMs expressed as a percentage of TNF- production compared with that in LPS-stimulated controls. Data are from 11 HIV-positive and six HIV-negative subjects. Total BAL cells (5 x 105/well) were incubated for 24 h with LPS (100 ng/ml) alone or with TPCK (50 µg/ml), BTEE (50 µg/ml), or D609 (50 µg/ml) after nonadherent cells were removed. Supernatant fluids were collected and assayed for TNF- by ELISA. The TNF- concentration in the LPS-stimulated samples was given the value of 100%, and the values obtained after incubation with the chemical protease inhibitors (TPCK, BTEE, and D609) were expressed relative to the value obtained for LPS-stimulated AMs. NS, not stimulated; LPS, stimulated with LPS.

Effects of TPCK and BTEE on TNF- and NF-B mRNA levels

To correlate protein production with TNF- mRNA and NF-B RNA concentrations, RNA was extracted after 4 and 24 h. The levels of TNF- and NF-B mRNAs were measured after 24-h incubation by RT-PCR and were detected by ELISA. The results were normalized for actin mRNA. Adding TPCK and BTEE to AMs rapidly (4 h) inhibited TNF- mRNA production, in contrast to the level of production obtained after LPS stimulation alone (Fig. 3). TNF- mRNA production was almost completely inhibited by these drugs at 4 h. After 24-h incubation, the levels of mRNA differed little between LPS-stimulated AMs treated with the chemical protease inhibitors and controls. The levels of NF-B mRNA in treated AMs were comparable to the levels obtained in LPS-stimulated AMs (data not shown). These results suggest that the chemical protease inhibitors decreased TNF- mRNA at 4 h, but did not affect NF-B mRNA .

View larger version (87K): [in this window] [in a new window]   FIGURE 3. The effects of TPCK and BTEE on TNF- mRNA extracted from AMs. BAL cells (5 x 105/well) were incubated for 16 h. Nonadherent cells were removed, and fresh medium was added with LPS (100 ng/ml) alone or with TPCK (50 µg/ml) or BTEE (50 µg/ml). After 4- and 24-h incubation, total RNA was extracted from the different wells using Trizol, reverse transcribed, and used in amplification reactions with TNF--specific primers. The amplified products were analyzed on an 1.5%-agarose gel and stained with 1% ethidium bromide. Lane 1, molecular mass markers; lane 3, AM plus LPS (4 h); lane 4, AM, LPS, and TPCK (4 h); lane 5, AM, LPS, and BTEE (4 h); lane 7, AM and LPS (24 h); lane 8, AM, LPS, and TPCK (24 h); lane 9, AM, LPS, and BTEE (24 h). Lanes 2 and 6 are empty. The arrow indicates the position of the amplified products at a m.w. of 325 bp.

Effects of phospholipase C (PLC) signaling pathway inhibitors on TNF- production by alveolar macrophages

Because NF-B activation is closely linked to the PLC signaling pathways, we studied the effects of an inhibitor (D609) of PLC on LPS-induced TNF- production by AMs from asymptomatic HIV-seropositive individuals. Adding D609 (50 µg/ml) to AMs almost completely inhibited LPS-stimulated TNF- production by AM (Fig. 2), suggesting a link between NF-B activation and the PLC pathway and indirectly with TNF- production.

Effects of TPCK and BTEE on NF-B activity in AMs

Various combinations of NF-B proteins form active NF-B heterodimers that bind to specific sequences in DNA. To determine whether the retarded bands by EMSA in untreated and treated cells were indeed NF-B, cell extracts were incubated with Ab against p65. To analyze the effects of adding TPCK and BTEE on the DNA binding of NF-B in AMs, nuclear extracts were prepared after various treatments of the AMs and were analyzed by EMSA. NF-B binding in untreated, unstimulated AMs (Fig. 4) was spontaneously detectable (lane 2), and it was enhanced by LPS stimulation (lane 3). After treating LPS-stimulated AMs with TPCK and BTEE, DNA binding in the nuclear extracts decreased substantially (lanes 4 and 5). The specificity of the binding was confirmed by competition with an excess of cold probe and by competition with an irrelevant probe (SP1; Fig. 4). Adding Ab against p65 resulted in a supershift, suggesting that the complex contains p65 subunits (Fig. 5).

View larger version (62K): [in this window] [in a new window]   FIGURE 4. The effects of the chemical protease inhibitors TPCK and BTEE on NF-B DNA binding in nuclear extracts from the AMs of HIV-infected subjects. AMs (5 x 105/well) were incubated in culture medium alone, in medium containing LPS (100 ng/ml), or in medium containing LPS plus 50 µg/ml of TPCK or BTEE. Nuclear extracts were prepared from the different wells and analyzed by EMSA. Extract (2–5 µg) was incubated in binding buffer for 5 min at 22°C before a 32P-labeled oligonucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3') was added. The complexes were resolved on an 8% native polyacrylamide gel and exposed to x-ray film for 16 h. A: Lane 1, HeLa cells (extract) control; lane 2, AMs and medium alone; lane 3, AMs and LPS; lane 4, AMs, LPS, and TPCK; lane 5, AMs, LPS, and BTEE; lanes 6 and 7, AMs, LPS and nonspecific probe (SP1). B: Lane 1, AMs and medium alone; lane 2, AMs and LPS; lane 3, AMs, LPS, and TPCK; lane 4, AMs, LPS, and BTEE; lanes 5 and 6, AMs and LPS; lanes 7 and 8, AMs, LPS, and nonspecific probe (SP1); lane 9, AMs, LPS, and competitor (cold NF-B). The arrows show the positions of bound complexes (large arrow) and the position of the unbound probe (small arrow).

View larger version (138K): [in this window] [in a new window]   FIGURE 5. The results of supershift EMSA. Supershift EMSA was performed with the addition of anti-p65 and was followed by incubation for 1 h at room temperature and then by electrophoresis on a native 5% gel. The dried gels were exposed to x-ray film for 16 h. Lane 1, unstimulated cells; lane 2, unstimulated cells and anti-p65; lane 3, LPS-stimulated cells; lane 4, LPS-stimulated cells and anti-p65. The arrow shows the positions of the supershifted bound complexes.

Effects of the chemical proteases on IB- and IB-ß

To examine the potential effects of TPCK, BTEE, and D609 on IB at the RNA and protein levels, RNA was extracted, and cytosolic extracts were prepared after 30, 60, and 180 min of treatment of the cells with LPS, TPCK, and BTEE. RNA was analyzed by RT-PCR with primers specific for IB- and IB-ß. IB- mRNA concentrations did not vary between 30 and 180 min, and there was no detectable difference in the concentration between untreated and unstimulated AMs and LPS-stimulated and treated macrophages. In contrast, IB-ß mRNA was barely detectable at 30 min, but it increased over time and was detected at 180 min under all culture conditions (Fig. 6).

View larger version (55K): [in this window] [in a new window]   FIGURE 6. The effects of the chemical protease inhibitors on IB- and IB-ß mRNA in AMs from HIV-seropositive subjects. AMs (5 x 105/well) were incubated with LPS in the presence of the chemical protease inhibitors. RNA was extracted from the various specimens after 30, 60, and 180 min and analyzed for IB- and IB-ß mRNA by RT-PCR. The amplified products were resolved on an 8% native polyacrylamide gel and stained with 1% ethidium bromide. The large arrow indicates IB-, and the small arrow indicates IB-ß. Lane 1, molecular mass markers; lane 2, AMs and medium alone (30 min); lane 3, AMs and LPS; lane 4, AMs, LPS, and TPCK (30 min); lane 5, AMs, LPS, and BTEE (30 min); lane 6, AMs, LPS, and D609 (30 min); lane 7, AMs and medium alone (60 min); lane 8, AMs and LPS (60 min); lane 9, AMs, LPS, and TPCK (60 min); lane 10, AMs, LPS, and BTEE (60 min); lane 11, AMs, LPS, and D609 (60 min); lane 12, AMs and medium alone (180 min); lane 13, AMs and LPS (IB- omitted; 180 min); lane 14, AMs, LPS, and TPCK; lane 15, AMs, LPS, and BTEE.

View larger version (73K): [in this window] [in a new window]   FIGURE 7. The results of immunoprecipitation and Western blot of protein extracts from AMs at 2, 4, and 24 h. A, Immunoprecipitation and Western blot with IB- after 30 min. Lane 1, Molecular markers. Subject 1: lane 2, protein extracts from unstimulated cells; lane 3, LPS-treated cells; lane 4, TPCK-treated cells; lane 5, BTEE-treated cells. Subject 2: lane 6, unstimulated cells; lane 7, LPS-stimulated cells; lane 8, TPCK-treated cells; lane 9, BTEE-treated cells. B, Immunoprecipitation and Western blot with IB- after 2 and 4 h. Subject 1 (2 h): lane 1, protein extracts from unstimulated cells; lane 2, LPS-stimulated cells; lane 3, TPCK-treated cells; lane 4, BTEE-treated cells; lane 5, molecular markers. Subject 1 (4 h): lane 6, unstimulated cells; lane 7, LPS-stimulated cells; lane 8, TPCK-treated cells; lane 9, BTEE-treated cells; lane 10, molecular markers.

To confirm HIV infection of lung cells used in this experiments, AMs and nonadherent cells were separated by plastic adherence and processed by PCR in suspension with HIV-specific primers (gag: SK38, and SK39) at 200 pmol/reaction. During PCR amplification, dUTP-11-DIG was incorporated in the amplified products and was later detected after incubation with an anti-DIG Ab-FITC-conjugate. PCR amplification for HIV DNA in nonadherent cells and in AMs of an asymptomatic HIV-seropositive subject revealed that 12% of the nonadherent cells (Fig. 8B) and 8% of the AMs contained HIV DNA (Fig. 8D). Thus, these distinct populations both harbor HIV DNA, and both may influence the amount of TNF- present in the lungs of HIV-seropositive subjects.

View larger version (40K): [in this window] [in a new window]   FIGURE 8. Detection of HIV DNA by PCR amplification of cells in suspension from an HIV-seropositive subject. The cells were separated by plastic adherence and processed separately for PCR amplification of HIV sequence with the specific primers as described in Materials and Methods. A, Nonadherent cells, no amplification, negative control (Taq omitted); B, nonadherent cells, positive amplification (Taq included); C, AMs, no amplification (Taq omitted); D, AMs, positive amplification (Taq included).

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

Stimulating AMs with LPS leads to the rapid expression of many genes that encode cytokines. The importance of NF-B in controlling this expression has been demonstrated in several systems (23), including patients with acute respiratory distress syndrome (24). NF-B binds to DNA as a dimer. The most prevalent NF-B dimer consists of the two subunits, p65 and p50, and is present in the cytosol in an inactive form bound to inhibitory proteins collectively named IB (IB-, -ß, and -). After activation of the cells, a cascade of events leads to NF-B dissociation from IB (25). The activation of NF-B is correlated with the phosphorylation of IB and its subsequent degradation. The loss of IB in the cytoplasm is followed by the appearance of NF-B in the nucleus. Although phosphorylation of IB occurs before its degradation, recent studies show that phosphorylation of IB alone does not release active NF-B (17).

Inflammatory cytokines, such as TNF- and IL-1, are produced by AMs and may affect HIV pathogenesis. Although NF-B regulatory sequences have been found in the promoter regions of TNF- and IL-ß, there is still debate concerning the extent to which NF-B is required for the expression of these genes (26).

In these experiments we used two chemical chymotrypsin-like protease inhibitors (TPCK and BTEE) that prevent NF-B translocation to the nucleus and therefore reduce TNF- production. Incubation of AMs for 24 h in the presence of TPCK and BTEE significantly decreased the production of TNF- by AMs, and this decrease was dose dependent. These compounds reduced TNF- production by AMs to constitutive levels. A similar effect has been described using murine AMs (27).

The factors controlling TNF- release by AMs during HIV-1 infection are not completely defined. LPS-induced cytokine releasein most systems is associated with increased NF-B DNA binding, but in AMs this association is less clear. Our results suggest that TNF- production by human alveolar macrophages from HIV-seropositive and -seronegative individuals is NF-B dependent. Immunoprecipitation followed by immunoblotting revealed that the complexes consisted of at least subunit p65. TPCK, but not BTEE, chemically modifies NF-B and may partially inhibit DNA binding by this mechanism. TPCK also works by blocking phosphorylation of IB-, thus keeping the IB-NF-B complex intact and preventing nuclear translocation of NF-B (28).

IB- and IB-ß concentrations did not differ substantially among the unstimulated, LPS-stimulated, and chemically treated specimens, as assessed by immunoblotting using polyclonal anti-IB- and anti-IB-ß Abs. This lack of difference suggests that TPCK and BTEE do not affect the level of expression of IB- and IB protein. The specific functions of IB-ß are not yet clear. In endothelial cells, a transient phase of NF-B activation may be mediated through IB-, and a more sustained phase may be mediated through IB-ß, because IB- is degraded more rapidly than IB-ß (29, 30, 31).

Protease inhibitors (such as TPCK and BTEE) block LPS-induced degradation of IB- and IB-ß and inhibit NF-B binding. At the mRNA level, they block the expression of TNF- and IL-1ß in monocytic cells (32). The chemical proteases inhibitors rapidly reduced TNF- mRNA expression in AMs. TNF- mRNA was inhibited as soon as 4 h after treatment; at 24 h, there was little difference in the concentration of TNF- mRNA compared to the pretreatment level. The mechanism responsible for the reappearance of TNF- mRNA after 24 h is not known. Conceivably, the chemical protease inhibitors are no longer active after 24 h. In B cells (70Z/3 cells), TPCK inhibited NF-B binding activity as well as IB- decay in response to PMA treatment (19). In AMs, addition of TPCK, BTEE, or both did not affect the expression of IB- after 2, 4, or 24 h.

Our results show that inhibiting PLC with a specific inhibitor, D609 (33), significantly reduced TNF- expression among LPS-stimulated macrophages in a dose-dependent manner. D609 is a complete inhibitor of acidic sphingomyelinase as well as PLC (34). A major pathway activated by tyrosine kinases involves PLC. NF-B activation by LPS is closely linked to the PLC signaling pathways. The PLC pathway is critical to the production of TNF- (35). One study of AMs from HIV-seronegative subjects showed that these events were protein kinase C-independent and PLC-tyrosine kinase-dependent (36). Another group found that protein kinase C inhibitors (staurosporine and sphingosine) suppressed LPS-induced TNF- production in AMs and in whole blood (40–90%) from HIV-seropositive subjects. AMs were less sensitive to protein kinase C inhibition than blood monocytes (37).

In conclusion, spontaneous TNF- release by AM from asymptomatic HIV-1-infected persons is no greater than that from healthy persons. After LPS stimulation, TNF- release in the supernatant fluids increased, and the process involved the induction of NF-B DNA binding associated with the PLC signaling pathway. These observations provide important insights into the mechanisms of TNF- release in the lungs of HIV-infected subjects. These findings may have implications concerning the pathogenesis of HIV-1 infection and the regulation of HIV-1 replication in the lungs of subjects with HIV-1 infection. Therapeutic strategies aimed at modifying the release of TNF- by AM may limit the local replication of HIV-1 in the lungs and prevent the pulmonary complications associated with HIV-1 infection.

	Acknowledgments

 
We thank the subjects who participated in this study, Robert Garland and Russell Morin for their excellent technical assistance, and Thomas Lang for editorial assistance.

	Footnotes

 
¹ This work was supported by a grant from the National Institutes of Health (RO1HL57875; to P.R.S.), the General Clinical Research Center at the New England Medical Center, which is funded by the National Center for Research Resources of the National Institutes of Health under Grant MO1-RR00054, and the Center for AIDS Research at Lifespan–Tufts–New England Medical Center (P30A142853).

² Address correspondence and reprint requests to Dr. Paul R. Skolnik, Department of Medicine, Division of Geographic Medicine and Infectious Diseases, New England Medical Center, 750 Washington Street, Boston, MA 02111. E-mail address:

³ Abbreviations used in this paper: AM, alveolar macrophages; TPCK, N-tosyl-L-phenylalanine chloromethyl ketone; BTEE, N-benzoyl-L-tyrosine ethyl ester; D609, tricyclodecan-9-yl-xanthogenate-potassium K; BAL, bronchoalveolar lavage; DIG, digoxigenin; PLC, phospholipase C.

Received for publication October 13, 1999. Accepted for publication November 15, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 

1. Murray, J. F., J. Mills. 1990. Pulmonary infectious complications of human immunodeficiency virus infection. Part I. Am. J. Respir. Dis. 141:1356.
2. Murray, J. F., J. Mills. 1990. Pulmonary infectious complications of human immunodeficiency virus infection. Part II. Am. J. Respir. Dis. 141:1582.
3. Wallace, J. M., N. I. Hansen, L. Lavange, J. Glassroth, B. L. Browdy, M. J. Rosen, P. A. Kvale, B. T. Mangura, L. B. Reichman, P. C. Hopewell, et al 1997. Respiratory disease trends in the pulmonary complications of HIV infection study cohort. Am. J. Respir. Crit. Care Med. 155:72.[Abstract]
4. Murray, J. F.. 1984. Pulmonary complications of the acquired immunodeficiency syndrome. N. Engl. J. Med. 310:1682.[Medline]
5. Lu, W., D. Israel-Biet. 1993. Virion concentration in bronchoalveolar lavage fluids of HIV infected patients. Lancet 342:298.[Medline]
6. Agostini, C., R. Sancetta, A. Cerutti, G. Semenzato. 1995. Alveolar macrophages as a cell source of cytokine hyperproduction in HIV-related interstitial lung diseases. J. Leukocyte Biol. 58:495.[Abstract]
7. Israel-Biet, D., J. Cadranel, K. Bedjord, J. M. Andrieu, A. Jeffrey, and P. Even. 1991. Tumor necrosis factor production in HIV-seropositive subjects: relationship with lung opportunistic infections and HIV expression in alveolar macrophages J. Immunol. 147:490.
8. Lebargy, F., A. Branellec, L. Deforges, J. Bignon, J. F. Bernaudin. 1994. HIV-1 in human alveolar macrophages from infected patients is latent in vivo but replicates after in vitro stimulation. Am. J. Res. Cell Mol. Biol. 10:72.[Abstract]
9. Nakata, K., M. Weiden, T. Harkin, D. Ho, W. N. Rom. 1995. Low copy number and limited variability of proviral DNA in alveolar macrophages from HIV-infected patients: evidence for genetic differences in HIV-1 between lung and blood macrophages. Mol. Med. 1:744.[Medline]
10. Nakata, K., W. N. Rom, Y. Honda, R. Condos, S. Kanegasali, Y. Cao, M. Weiden. 1997. Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am. J. Respir. Crit. Care Med. 55:996.
11. Pearce, T. E., M. Nowakowski, E. Eden, Z. B. Hung, P. Steiner, M. Shahabuddin, M. J. Potash, D. J. Volsky. 1993. Uniform detection of HIV-1 in alveolar macrophages of pediatric but not adult AIDS patients. J. Leukocyte Biol. 53:722.[Abstract]
12. Cox, R. A., G. T. Anders, P. J. Cappelli, J. E. Johnson, H. M. Blanton, B. J. Seaworth, R. L. Treasure. 1990. Production of tumor necrosis factor- and interleukin-1 by alveolar macrophages from HIV-1 infected persons. AIDS Res. Hum. Retroviruses 6:431.[Medline]
13. Du, E. J., W. J. Maury, T. M. Folks, A. S. Fauci, A. B. Rabson. 1989. Tumor necrosis factor activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-B sites in the long terminal repeat. Proc. Natl. Acad. Sci. USA 86:5974.[Abstract/Free Full Text]
14. Baldwin, A. S.. 1996. The NFB and IB proteins: new discoveries and insights. Annu. Rev. Immunol. 14:649.[Medline]
15. Baeuerle, P. A., D. Baltimore. 1996. NF-B ten years after. Cell 87:13.[Medline]
16. Liou, H. C., D. Baltimore. 1993. Regulation of the NF-kappa B/Rel transcription factor and IB inhibitor system. Curr. Opin. Cell Biol. 5:477.[Medline]
17. Miyamoto, S., M. Maki, M. J. Schmitt, M. Hatanaka, I. M. Verma. 1994. Tumor necrosis factor -induced phosphorylation of IB is a signal for its degradation but not dissociation from NF-B. Proc. Natl. Acad. Sci. USA 91:12740.[Abstract/Free Full Text]
18. Harper, J. W., K. Hemmi, J. C. Powers. 1985. Reaction of serine proteases with isocoumarins: discovery of 3,4-dichloroisocoumarin, a new general mechanism-based serine protease inhibitor. Biochemistry 4:2219.
19. Henkel, T., T. Machleidt, I. Alkalay, M. Kronke, Y. Ben-Neriah, P. A. Baeuerle. 1993. Rapid proteolysis of IB- is necessary for activation of transcription factor NF-B. Nature 365:182.[Medline]
20. Abate, A., H. Schroder. 1998. Protease inhibitors protect macrophages from lipopolysaccharride-induced toxicity: possible role of NF-B. Life Sci. 62:1081.[Medline]
21. Pinkston, P., N. Pelletier, C. Arena, J. Schock, R. Garland, R. M. Rose. 1995. Quantitative culture of HIV-1 from bronchoalveolar lavage cells. Am. J. Respir. Crit. Care Med. 152:254.[Abstract]
22. Andrews, N. C., D. V. Faller. 1991. A rapid micropreparation technique for extraction of DNA-binding proteins from limited numbers of mammalian cells. Nuc. Acids Res. 19:2499.[Free Full Text]
23. Baeuerle, P. A., T. Henkel. 1994. Function and activation of NF-B in the immune system. Annu. Rev. Immunol. 12:141.[Medline]
24. Schwartz, M. D., E. E. Moore, F. A. Moore, R. Shankar, P. Moine, J. B. Haemel, E. Abraham. 1996. Nuclear factor-B is activated in alveolar macrophages from patients with acute respiratory distress syndrome. Crit. Care Med. 24:1285.[Medline]
25. Donald, R., D. W. Ballard, J. Hawiger. 1995. Proteolytic processing of NF-B/IB in human monocytes. J. Biol. Chem. 270:9.[Abstract/Free Full Text]
26. Yao, J., N. Mackman, T. S. Edgington, S. T. Fan. 1997. Lipopolysaccharide induction of the tumor necrosis factor- promoter in human monocytic cells. J. Biol. Chem. 272:17795.[Abstract/Free Full Text]
27. Lo, C. J., M. Fu, B. Kim. 1997. Macrophage TNF mRNA expression is modulated by protease inhibitors. J. Surg. Res. 69:408.[Medline]
28. Finco, T.S., A. A. Beg, Jr A. S. Baldwin. 1994. Inducible phosphorylation of IB- is not sufficient for its dissociation from NF-B and is inhibited by protease inhibitors. Proc. Natl. Acad. Sci. USA 91:11884.[Abstract/Free Full Text]
29. Cheng, J. D., R. P. Ryseck, R. M. Attar, D. Dambach, R. Bravo. 1998. Functional redundancy of the nuclear factor B inhibitors IB and IBß. J. Exp. Med. 188:1055.[Abstract/Free Full Text]
30. Johnson, D. R., I. Douglas, A. Jahnke, S. Ghosh, J. S. Pober. 1996. A sustained reduction in IB-ß may contribute to persistent NF-B activation in human endothelial cells. J. Biol. Chem. 271:16317.[Abstract/Free Full Text]
31. Thompson, J. E., R. J. Phillips, H. Erdjument-Bromage, P. Tempst, S. Ghosh. 1995. IB-ß regulates the persistent response in a biphasic activation of NF-B. Cell 80:573.[Medline]
32. Haas, M., S. Page, M. Page, F. J. Neumann, N. Marx, M. Adam, H. M. Ziegler-Heitbrock, D. Neumeier, K. Brand. 1998. Effect of proteasome inhibitors on monocytic IB-, -ß depletion, NFB activation, and cytokine production. J. Leukoyte Biol. 63:395.[Abstract]
33. Lo, C. J., I. Garcia, H. G. Cryer, R. V. Maier. 1996. Calcium and calmodulin regulate lipopolysaccharide-induced alveolar macrophage production of tumor necrosis factor and procoagulant activity. Arch. Surg. 131:44.[Abstract]
34. Wiegmann, K., S. Schutze, T. Machleidt, D. Witte, M. Kronke. 1994. Functional dichotomy of neutral and acidic shingomyelinases in tumor necrosis factor signaling. Cell 78:1005.[Medline]
35. Carter, A. B., M. M. Monick, G. W. Hunninghake. 1998. Lipopolysaccharide-induced NF-B activation and cytokine release in human alveolar macrophages is PKC-independent and TK- and PLC-dependent. Am. J. Respir. Cell Mol. Biol. 18:384.[Abstract/Free Full Text]
36. Tschaikowsky, K.. 1994. Protein kinase C inhibitors suppress LPS-induced TNF production in AM and in whole blood: the role of encapsulation into liposomes. Biochim. Biophys. Acta 1222:113.[Medline]
37. Schutze, S., K. Potthoff, T. Machleidt, D. Berkovic, K. Wiegmann, M. Kronke. 1992. TNF activates NF-B by phosphatidylcholine-specific phospholipase C-induced "acidic" sphingomyelin breakdown. Cell 71:765.[Medline]

This article has been cited by other articles:

				S. D. Tachado, J. Zhang, J. Zhu, N. Patel, and H. Koziel HIV Impairs TNF-{alpha} Release in Response to Toll-Like Receptor 4 Stimulation in Human Macrophages In Vitro Am. J. Respir. Cell Mol. Biol., December 1, 2005; 33(6): 610 - 621. [Abstract] [Full Text] [PDF]

				J. Zhang, J. Zhu, A. Imrich, M. Cushion, T. B. Kinane, and H. Koziel Pneumocystis Activates Human Alveolar Macrophage NF-{kappa}B Signaling through Mannose Receptors Infect. Immun., June 1, 2004; 72(6): 3147 - 3160. [Abstract] [Full Text] [PDF]

				S B Gordon and R C Read Macrophage defences against respiratory tract infections: The immunology of childhood respiratory infections Br. Med. Bull., March 1, 2002; 61(1): 45 - 61. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Mathys, J.-M. Articles by Skolnik, P. R. Search for Related Content PubMed PubMed Citation Articles by Mathys, J.-M. Articles by Skolnik, P. R.